Dr. Ankur Nandan Varshney is a renowned Medical Oncologist, Hemato-Oncologist, and Bone Marrow Transplant Specialist with over 15 years of experience in advanced cancer care, currently serving as Senior Consultant in Medical Oncology, Hematology & Bone Marrow Transplant at Medanta Hospital, Noida. He completed his MBBS and MD in Internal Medicine from the Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), and went on to pursue his DM in Medical Oncology with super-specialty training at the All India Institute of Medical Sciences (AIIMS), New Delhi, one of India's most prestigious institutions for oncological training. He is also certified by the European Society for Medical Oncology (ESMO), reflecting his alignment with international standards in cancer care. Dr. Varshney specialises in the treatment of both solid tumours and blood cancers, with expertise spanning breast, lung, gastrointestinal, gynaecological, genitourinary, and head & neck cancers, as well as haematological malignancies including leukaemia, lymphoma, and multiple myeloma. He is particularly skilled in targeted therapy, immunotherapy, precision oncology, and bone marrow transplantation, and is committed to delivering evidence-based, personalised cancer care using the latest therapeutic advancements. His approach encompasses the full continuum of oncological care, from cancer screening and early detection to active treatment, supportive care, and survivorship. An accomplished researcher and academic contributor, Dr. Varshney has published numerous papers in reputed national and international peer-reviewed journals and has presented scientific research at prestigious global conferences including ASCO, ESMO, and SOHO. He has been recognised with the Outstanding Clinician in Medical Oncology Award and the Emerging Oncologist Award, and has received multiple national and international research grants and scholarships. He also regularly contributes to public health awareness on cancer prevention, early detection, modern therapies, and survivorship through leading print and digital media.